PatentJun 18, 2026, 07:26 AM
CervoMed Inc. Secures New Patent for Dementia Drug Candidate Neflamapimod
AI Summary
CervoMed Inc. announced on June 16, 2026, that it received a notice of allowance from the United States Patent and Trademark Office for a new patent. This patent specifically protects the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients without significant Alzheimer's disease-like tau pathology. The expected intellectual property protection extends into 2042, not including any potential patent term extensions.
Key Highlights
- CervoMed Inc. received a notice of allowance from the USPTO for a new patent.
- The patent protects the use of neflamapimod for treating dementia with Lewy bodies.
- Intellectual property protection is expected to extend into 2042, excluding potential patent term extensions.
Price Impact
More from CRVO